Vascular surgery is a surgical subspecialty in which vascular diseases involving the arteries, veins, or lymphatic vessels, are managed by medical therapy, minimally-invasive catheter procedures and surgical reconstruction. The specialty evolved from general and cardiovascular surgery where it refined the management of…
An institutional-grade, numbers-driven thesis on BTAI — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of July 4, 2026, TradersQuant's model rates BTAI (BTAI) 54/100. BTAI is covered in the Unknown sector. The score blends valuation, growth, earnings quality and momentum into a single grade.
On the fundamentals, BTAI shows trailing revenue of $642000. This page also tracks BTAI's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
BTAI currently carries a TradersQuant composite score of 54/100, which we read as a neutral-to-watch signal. This is research, not financial advice — always combine it with your own judgement.
TradersQuant generates a 12-month, three-scenario (bull/base/bear) model forecast for BTAI. Open the live page for current figures.
TradersQuant publishes a model-based 12-month price prediction for BTAI, and every call is logged and graded publicly against the S&P 500. Open the live page for current figures.
We deliberately don't publish 2030 price predictions for BTAI — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
BTAI does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
